FSTL1-induced immune dysfunction leads to tumor bone metastases [17] and activation of immune evasion mechanisms in patients with non-small cell lung cancer (NSCLC) through the FSTL1-DIP2A axis [18]. Here, FSTL1 is linked to non-small cell lung carcinoma.